Identification of Severe Combined Immunodeficiency by T-Cell Receptor Excision Circles Quantification Using Neonatal Guthrie Cards
Objective
To assess the feasibility of T-cell receptor excision circles (TRECs) quantification for neonatal mass screening of severe combined immunodeficiency (SCID).
Study design
Real-time PCR based quantification of TRECs for 471 healthy control patients and 18 patients with SCID with various genetic abnormalities (IL2RG, JAK3, ADA, LIG4, RAG1) were performed, including patients with maternal T-cell engraftment (n = 4) and leaky T cells (n = 3).
Results
TRECs were detectable in all normal neonatal Guthrie cards (n = 326) at the levels of 104 to 105 copies/μg DNA. In contrast, TRECs were extremely low in all neonatal Guthrie cards (n = 15) and peripheral blood (n = 14) from patients with SCID, including those with maternal T-cell engraftment or leaky T cells with hypomorphic RAG1 mutations or LIG4 deficiency. There were no false-positive or negative results in this study.
Conclusion
TRECs quantification can be used as a neonatal mass screening for patients with SCID.
BCG, Bacillus Calmette-Guérin, BMT, Bone marrow transplantation, CMV, Cytomegalovirus, FISH, Fluorescent in situ hybridization, HSCT, Hematopoietic stem cell transplantation, PB, Peripheral blood, PCR, Polymerase chain reaction, sjTRECs, Signal joint TRECs, SCID, Severe combined immunodeficiency, TCR, T-cell receptor, TRECs, T-cell receptor excision circles, UCB, Umbilical cord blood
To access this article, please choose from the options below
Supported by grants from the Ministry of Defense, Ministry of Health, Labour and Welfare Kawano Masanori Foundation for Promotion of Pediatrics, Jeffrey Modell Foundation, and The Mother and Child Health Foundation.
The authors declare no conflicts of interest.
PII: S0022-3476(09)00505-8
doi:10.1016/j.jpeds.2009.05.026
© 2009 Mosby, Inc. All rights reserved.
Refers to article:
- Long-term Clinical Outcome of Patients with Severe Combined Immunodeficiency Who Received Related Donor Bone Marrow Transplants without Pretransplant Chemotherapy or Post-transplant GVHD Prophylaxis , 12 October 2009
